Opinion: Landmines Await Vinay Prasad’s Successor at the FDA
13 Apr 20264 min read0 viewsVerified Feed
GIST (Key Takeaways)
Vinay Prasad’s short yet two-act tenure at the FDA was wild. How does anyone follow him as the new leader of biologics oversight at the agency?
Someone I know at the FDA joked to me recently that I should be the new director of the Center for Biologics Evaluation and Research (CBER) after Prasad. I literally laughed out loud at how comical that sounded, but it got me thinking: Who would be both willing to do it and could get picked?
Further, what’s awaiting them? Prasad became a favorite punching bag of many, including the Wall Street Journal editorial board and right-wing activists like Laura Loomer .
They are teed up to clobber the next person, too. Continue to STAT+ to read the full story...
Clinical Editorial
STAT News published a clinical update in Research Highlights on 13 Apr 2026.
The item focuses on Opinion: STAT+: Landmines await Vinay Prasad’s successor at the FDA.
Review the original article for the full source wording and details.
Source Reference
Read the full original publication from the source journal or publisher link below.